HIGD1AP17

Across TCGA pan-cancer cohorts, HIGD1AP17 RNA is linked to patient survival in 14 of 34 cancer types, making it the most broadly survival-associated HIGD1AP17 data layer.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher HIGD1AP17 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated HIGD1AP17 expression acts as an unfavorable survival marker, although some lineages such as CESC and LAML show a favorable association.

DLBC, UVM, and READ are the cancer types where HIGD1AP17 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	OS	Tertile	All	0.469	0.939	<.001	171	view →
UVM	DFS	Tertile	III,IV	0.106	0.707	<.001	90	view →
READ	DFS	Tertile	III,IV	0.055	0.757	<.001	63	view →
TGCT	DFS	Tertile	II,III,IV	0.015	0.919	<.001	36	view →
LUSC	OS	Tertile	All	0.557	0.685	.005	33	view →
ACC	DFS	Tertile	III,IV	0.039	0.381	.008	27	view →
UCS	OS	Tertile	II,III,IV	0.247	0.621	.046	18	view →
CESC	OS	Tertile	IV	0.779	0.190	.025	18	view →
MESO	OS	Tertile	IV	0.077	0.592	.019	18	view →
LAML	DFS	Median	All	0.620	0.329	.007	16	view →
THYM	DFS	Tertile	All	0.641	0.896	.026	15	view →
LIHC	OS	Tertile	III,IV	0.184	0.622	.008	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 14 lineages.

HIGD1AP17–DLBC (OS)

Open the DLBC breakdown →